Skip to content
DataLookout
Menu

NCT06669403

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

StatusRecruiting
PhasePhase 1
SponsorOp-T LLC
Primary completion (estimated)

At risk: Primary completion moved at least 10 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Mar 2027 Show 5 more changesShow less
    • Recruitment opened
    • Eligibility criteria expanded, about 21 words
    • Study sites: 1 to 2
    • Start date changed from estimate of Dec 2025 to Mar 9, 2026
    • Secondary endpoints: details revised at 2 of 5 entries
  2. Notable Start date: Jun 2025 to Dec 2025v3
  3. Notable Start date: Feb 2025 to Jun 2025
    • Site contact updated
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence of treatment-emergent adverse events (TEAEs)
Timeframe: 30 days
Incidence of serious adverse events (SAEs)
Timeframe: 30 days
Incidence of TEAEs leading to study drug discontinuation
Timeframe: 30 days
Incidence and characteristics of presumed infusion reactions
Timeframe: 30 days

Secondary (1)

To measure the serum pharmacokinetics of OPT101

Arms and interventions

0.9% Sodium Chloride Injection USPPlacebo comparator

Placebo will be 50mL normal saline (Sodium Chloride), USP sterile solution provided in a 50mL pre-packaged Intravenous (IV) bag.

OPT101Experimental

OPT101 (15-mer peptide) will be provided across 2 cohorts at 1.1 (cohort 1) and 2.8 mg/kg (cohort 2) doses . On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.

Drugs: OPT101

Other: Placebo

Sites

2 sites in 1 country